PDCD1 and neoplasm: ILC3s are also the most prevalent ILC subset in the malignant pleural effusions of many different cancers, and the variable expression of PD-1 on these ILC3s is suggested to limit their anti-tumor activity through interactions with its ligand PD-L1 on tumor cells [107].